Robert C. Doebele, MD, PhD

Robert C. Doebele, MD, PhD, shares his thoughts on what the next steps are for entrectinib in patients with&nbsp;<em>ROS1</em>-positive non&ndash;small cell lung cancer. In August of 2019, the FDA granted approval to this agent as treatment of patients with metastatic NSCLC who are&nbsp;<em>ROS1</em>-positive.

Robert C. Doebele, MD, PhD, discusses resistance in patients with ROS1-positive lung cancer.

Robert C. Doebele, MD, PhD, associate professor in the Division of Medical Oncology at the University of Colorado, discusses the significance of brain metastases in patients with non&ndash;small cell lung cancer.&nbsp;

Robert C. Doebele, MD, PhD, associate professor, Division of Medical Oncology, University of Colorado, discusses the significance of the results of a trial exploring entrectinib in patients with&nbsp;ROS1-positive non&ndash;small cell lung cancer (NSCLC).